Xenical(orlistat)
Alli, Xenical (orlistat) is a small molecule pharmaceutical. Orlistat was first approved as Xenical on 1998-07-29. It is used to treat obesity in the USA. It has been approved in Europe to treat obesity. The pharmaceutical is active against pancreatic triacylglycerol lipase. In addition, it is known to target diacylglycerol lipase-beta, diacylglycerol lipase-alpha, and lysophosphatidylserine lipase ABHD12.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Alli, Xenical
Drug Products
FDA
EMA
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| obesity | EFO_0001073 | D009765 | E66.9 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
56 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | — | 7 | 3 | 10 | 10 | 30 |
| Overweight | D050177 | E66.3 | 2 | 1 | — | 1 | 6 | 9 | |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | 2 | — | 3 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | 1 | — | 1 | — | 2 |
| Fatty liver | D005234 | — | — | — | 2 | — | 2 | ||
| Bulimia | D002032 | F50.2 | — | — | — | 1 | 1 | 2 | |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | 1 | — | 1 |
| Hepatitis c | D006526 | B19.2 | — | — | — | 1 | — | 1 | |
| Hepatitis | D006505 | HP_0012115 | K75.9 | — | — | — | 1 | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Weight loss | D015431 | HP_0001824 | — | — | 1 | — | 1 | 2 | |
| Female infertility | D007247 | EFO_0008560 | N97 | — | — | 1 | — | — | 1 |
| Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Metabolic syndrome | D024821 | EFO_0000195 | E88.81 | 1 | 3 | — | — | 1 | 4 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | 1 | — | — | 1 | 2 |
| Nutrition disorders | D009748 | EFO_0001069 | — | 1 | — | — | — | 1 | |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | 1 | — | — | — | 1 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | 1 | — | — | — | 1 |
| Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | 1 | — | — | — | 1 |
| Hypertriglyceridemia | D015228 | EFO_0004211 | — | 1 | — | — | — | 1 | |
| Hyperlipoproteinemia type i | D008072 | Orphanet_411 | E78.3 | — | 1 | — | — | — | 1 |
| Hyperlipoproteinemia type v | D006954 | Orphanet_70470 | E78.3 | — | 1 | — | — | — | 1 |
Indications Phases 1
No data
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anovulation | D000858 | — | — | — | — | 1 | 1 | ||
| Hyperlipidemias | D006949 | EFO_0003774 | E78.5 | — | — | — | — | 1 | 1 |
| Infertility | D007246 | EFO_0000545 | — | — | — | — | 1 | 1 | |
| Feeding and eating disorders | D001068 | F50 | — | — | — | — | 1 | 1 | |
| Crigler-najjar syndrome | D003414 | Orphanet_205 | E80.5 | — | — | — | — | 1 | 1 |
| Therapeutic equivalency | D013810 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ORLISTAT |
| INN | orlistat |
| Description | Orlistat is a carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug. It has a role as an EC 3.1.1.3 (triacylglycerol lipase) inhibitor, a bacterial metabolite, an EC 2.3.1.85 (fatty acid synthase) inhibitor and an anti-obesity agent. It is a beta-lactone, a L-leucine derivative, a member of formamides and a carboxylic ester. |
| Classification | Small molecule |
| Drug class | enzyme inhibitors: gastrointestinal lipase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCCCCCCCCC[C@@H](C[C@@H]1OC(=O)[C@H]1CCCCCC)OC(=O)[C@H](CC(C)C)NC=O |
Identifiers
| PDB | — |
| CAS-ID | 96829-58-2 |
| RxCUI | 37925 |
| ChEMBL ID | CHEMBL175247 |
| ChEBI ID | — |
| PubChem CID | 3034010 |
| DrugBank | DB01083 |
| UNII ID | 95M8R751W8 (ChemIDplus, GSRS) |
Target
Alternate
DAGLB
DAGLB
DAGLA
DAGLA
ABHD12
ABHD12
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 28,148 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
720 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more